...Pharmaceutical Co. Ltd. are both mAbs in Phase I that target TNFSF13, while telitacicept (RC18, Tai'ai...

...cancer, autoimmune disease and ophthalmology, with at least two programs in pivotal studies. Its telitacicept (RC18...

...than 10 biologics for autoimmune, cancer and ophthalmology, including commercialization of its two lead candidates RC18...
...and the HER2-targeting antibody-drug conjugate (ADC) RC48. The company has submitted a China NDA for RC18...

...II compound cenerimod is a small molecule S1PR1 modulator; and RemeGen’s Phase II compound telitacicept (RC18...

...RemeGen, a subsidiary of Yantai Rongchang Pharmaceutical Co. Ltd., said its TACI-Fc fusion protein telitacicept (RC18...